We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Aml4.2

Amla Research

Mostly mechanism / observationalHigh safety

5 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Amla studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality meta-analyses and randomised trials published 2019–2025 with a typical study size of 98 participants.

Based on 5 studies · 1 meta-analysis · 3 RCTs · 347 total participants

Confidence

Moderate

By outcome

Glucose & metabolicSignificant fasting-glucose reduction in pooled RCT data, though trials are short and small · 4-12 weeks · Improved lipid ratios, lowered CRP, and reduced oxidative-stress markers in metabolic-syndrome subjects · 8-12 weeks
Mostly mechanism / observational3 studies
Heart & blood pressureModest reductions in total cholesterol, LDL, and triglycerides; improved endothelial function in several small RCTs · 8-12 weeks
Too few graded studies1 study

Active research area

3 studies in the last 5 years · Latest meta-analysis: 2023

20192025

1RCTn=150 · medium study2021

Adding Phyllanthus emblica 500 mg twice daily to standard therapy produced no additional reduction in blood pressure, lipids, oxidative status, or hs-CRP over 12 weeks.

Shanmugarajan D, Girish C, Harivenkatesh N, et al. · Phytother Res (2021)

No additional reduction in systolic or diastolic blood pressure versus placebo
No improvement in lipid profile, oxidant/antioxidant status, HbA1c, arterial stiffness, or hs-CRP
Larger (150-patient), rigorous double-blind RCT — a clear negative result that tempers the positive trials

View source

2Meta-Analysis2023

Pooling five RCTs, amla supplementation significantly reduced CRP, fasting blood glucose, LDL, total cholesterol, and triglycerides, and increased HDL.

Setayesh L, Haghighat N, Rasaei N, et al. · Diabetes Metab Syndr (2023)

Significant reduction in total cholesterol, LDL-c, and triglycerides (all p < 0.001)
Significant reduction in fasting blood glucose (p < 0.001) and CRP (p = 0.002)
Significant increase in HDL-c (p < 0.001)

View source

3RCTn=98 · small study2019

Amla extract 500 mg twice daily for 12 weeks significantly lowered total cholesterol, triglycerides, LDL, and VLDL versus placebo in dyslipidemic patients.

Upadya H, Prabhu S, Prasad A, et al. · BMC Complement Altern Med (2019)

Significant reductions in total cholesterol (p = 0.0003), triglycerides (p = 0.0003), LDL-C (p = 0.0064), and VLDL-C (p = 0.0001)
39% reduction in atherogenic index of plasma (p = 0.0177)
Cholesterol reduction achieved without depleting CoQ10, unlike statins

View source

4RCTn=59 · small study2019

Phyllanthus emblica extract significantly improved endothelial function, oxidative stress, inflammation, and lipid profile in metabolic-syndrome subjects, most at 500 mg twice daily.

Usharani P, Merugu PL, Nutalapati C. · BMC Complement Altern Med (2019)

Significant improvement in reflection index (endothelial function) at 8 and 12 weeks (p < 0.001)
Improved nitric oxide, glutathione, and malondialdehyde; reduced hsCRP (up to -53.77%)
Reduced total cholesterol, LDL, and triglycerides; raised HDL

View source

5Open-Labeln=40 · small study2025

In obese adults, 1 g/day amla extract significantly reduced visceral and subcutaneous fat, waist circumference, BMI, and improved lipid profile over 90 days.

Suhag D, Rathore R, Yadav A, et al. · Complement Med Res (2025)

Significant reduction in visceral fat, subcutaneous fat, waist circumference, BMI, and body weight (p < 0.05)
Increased skeletal muscle mass and improved lipid profile (p < 0.05)
Open-label design (not blinded) and small sample limit confidence

View source

View in Research Library

Amla Research

Mostly mechanism / observational

Antihypertensive and pleiotropic effects of Phyllanthus emblica extract as an add-on therapy in patients with essential hypertension-A randomized double-blind placebo-controlled trial.

The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.

A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.

Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study.

Effect of Amla Extract on Body Mass Index, Waist Circumference, Total Body Fat, Visceral Fat, Skeletal Muscle Mass, Body Age, and Related Parameters: A Randomized, Open-Label Clinical Study in Obese Participants.